Introduction
Similar to many countries in Africa, the prevalence of epilepsy in Cameroon is higher than that in industrialized countries and has been reported to vary from 5.5 to 136 per thousand population. [1] [2] [3] [4] [5] The variability in reports may be due to methodological differences. It is also possible that variability could be due to differences in etiology between regions in Cameroon. Epilepsy in Ngie appears to be an early childhood onset disorder that lasts well into adulthood, being life-long in most cases. Unconfirmed reports indicate that in most individuals the seizures appear to be primary generalized, but in some cases appear to be focal in onset (e.g. blinking, staring, visual phenomena, etc.), with evolution to generalized convulsions. There are many anecdotal accounts of severe seizure-related injuries in Ngie including burns and falls, as well as deaths from uncontrolled status epilepticus and drowning.
Purpose: The prevalence of epilepsy in Cameroon is higher than that of the industrialized world and other developing countries. Neurocysticercosis due to Taenia solium infestation has been reported as a major cause of epilepsy in some parts of Cameroon although there are some conflicting data. The prevalence of epilepsy is especially high in the Momo division of the North-West Province of Cameroon. We hypothesized that individuals with epilepsy in this region have a higher percentage of seropositivity to T. solium than matched controls. Methods: We conducted a case-control study in the Momo subdivision of Ngie. Individuals with epilepsy were recruited from the health centers in Ngie. Control subjects were selected from 19 Ngie villages. Potential cases of people with epilepsy (PWE) were identified through a questionnaire applied by trained field workers, using history of epileptic seizures as a key indicator. Blood samples were taken from all consenting individuals by finger prick, stored in StabilZyme Select, and assayed for antibodies to T. solium in an Atlanta based reference laboratory. Results: We accrued 249 patients with epilepsy, of whom 237 met the inclusion criteria, and 245 agematched controls. There was no significant difference in seropositivity to T. solium between those individuals with epilepsy (5%) and controls (4.9%). Conclusions: Our data do not support the hypothesis that epilepsy is associated with seropositivity to T. solium. It is highly unlikely that cysticercosis plays a causative role in the high prevalence of epilepsy in this region of Cameroon.
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The cause of the high prevalence of epilepsy in this region has not been determined. Neurocysticercosis arising from Taenia solium infection has been postulated to be the major cause of epilepsy in some parts of Cameroon, as it is in other developing countries. [6] [7] [8] Zoli et al. 9 in an uncontrolled study in three rural localities in the West and North-West regions of Cameroon, used an enzyme-linked immunosorbent assay for both circulating antigen (Ag-ELISA) and antibody (Ab-ELISA) detection in individuals who had epilepsy. These authors concluded that T. solium cysticercosis appeared to be an important cause of epilepsy in Cameroon; however, this finding has not been confirmed in all studies, 1 suggesting that the etiology of epilepsy may vary by region.
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Throughout the North-West region of Cameroon, including the Momo division, pig rearing is very common and pigs are often kept in close proximity to houses. Since neurocysticercosis is endemic in less developed countries where pigs are raised as a food source, 11, 12 this factor raises the question of whether neurocysticercosis has a causative role in the incidence of epilepsy in this region. The purpose of this study was to test the hypothesis that neurocysticercosis is responsible for the high prevalence of epilepsy in the Ngie sub-division of Momo. More specifically, the primary objective was to compare the serological status of T. solium in individuals with epilepsy with matched, unrelated, case controls in the sub-division of Ngie. A secondary objective was to obtain a demographic profile of those individuals identified with epilepsy in this region, including other potential risk factors for epilepsy.
Methods

Ethics approvals and consent
This study was carried out under the ethical precepts found in the World Medical Association Declaration of Helsinki (http:// www.wma.net/e/policy/b3.htm). Ethics approval was obtained from the Research Ethics Board of the Hospital for Sick Children, Toronto, Canada, the Cameroon National Ethics Committee, and the local district ethics committee (Alpha Royal Clinic). Community consent was first obtained by having medical health volunteers explain the goal of the study to village traditional and administrative and health authorities. Community information sessions were then conducted, the purpose of which was to allow individuals to discuss their questions and concerns. Village coordinators, who helped study participants to complete the questionnaires, were trained on how to obtain informed consent. In addition, the coordinators determined who could read. Ngie language is not written. Therefore, to make things clear, a translated version of the informed consent was made on an audiotape and played where necessary. Following these community meetings, potential subjects and controls were provided further information and if they agreed to participate, consent for the administration of the questionnaire and blood sampling was obtained.
Participants
Individuals with epilepsy were recruited from local households in the 19 villages and from the two health centers (clinics) in the sub-division of Ngie, Momo Division, North-West Cameroon. Persons with epilepsy had been attending these health centers for distribution of antiepileptic medication (phenobarbital). Those with epilepsy were defined as having had at least two unexplained and unprovoked seizures occurring within a time range of >24 h. This was to include all types of partial and/or generalized seizures. 13 A total of 57 persons with epilepsy were excluded for the following reasons. Controls with no history of epilepsy from the 19 villages in Ngie sub-division volunteered to participate after hearing about the study at community meetings and from village coordinators. They were then matched for age and sex by group with subjects in the epilepsy group. Exclusion criteria for controls were a history of epilepsy in the subject or in the family. It should be noted however, that it was difficult to be completely sure whether controls were distantly related to subjects with epilepsy.
Questionnaires
An adapted form of a previously validated epilepsy screening questionnaire 14 was applied by trained field workers to identify potential people with epilepsy. This questionnaire was developed for the detection of epileptic seizures in epidemiological studies in developing countries. This questionnaire has been validated on a population of 72,121 people, and has been shown to have a sensitivity of 79.3%, a specificity of 92.9%, a positive predictive value of 18.3% and a negative predictive value of 99.6%. 14, 15 Following completion of this validated epilepsy questionnaire, participants completed a second, more comprehensive, demographic/medical questionnaire developed in Limoges France, and was previously and has been validated and used by the Pan African Association of Neurological Sciences in many African countries, including Cameroon. 4, 5, 16 Except for the demographic and epilepsy-related data, the results from this questionnaire are beyond the scope of the current paper.
Procedure
Individuals in 19 villages were designated as coordinators and trained to administer the screening questionnaire. Training was completed by a local investigator (JA) and a member of the research team from Canada (IE).
Potential participants from each village in Ngie were screened door to door by the village coordinators to identify all individuals who had epilepsy and to obtain volunteers for the control group. Those consenting to participate were convened to the nearest local health center, where a local physician with special training in neurology/epileptology (SAA) reviewed each individual's medical history, and further confirmed those with a history of epilepsy and the respective controls. Some individuals who initially presented themselves as controls were examined and discovered to be persons with epilepsy and were consequently recruited as subjects. Others presented themselves as having epilepsy, but had only experienced either one epileptic seizure or were deemed not to have had epileptic seizures, and were thus excluded from the study. In either case they were referred to the nearest health facility for assessment. Medication (phenobarbital) was prescribed to newly diagnosed patients and minor dose adjustments were made for people with uncontrolled seizures. All patients were referred to the health centers for follow-up.
Blood sampling/serology
Supplies for blood samples were brought to Cameroon by a research team member (IE) from Canada. The drawing of blood for serologies, storage of serology samples, and transfer of all serology samples for analysis to the Centers for Disease Control in Atlanta (CDC) was coordinated by the local team of investigators (IT, JA, AKN). The method used for collecting measured whole blood with quantitative recovery of antibodies to T. solium was described by Handali et al. 17 Briefly, blood samples were obtained by a qualified medical technician under sterile conditions by finger stick, and were collected on filter paper, which was immediately immersed in extraction/preservative (StabilZyme TM) and frozen. Blood samples from both the epilepsy and control groups were obtained at one of two health centers. The samples were stored at the Catholic Medical Health Centre, Mambu Bafut until shipped in cold packs to the CDC for detection of T. solium specific antibodies using the lentil lectin affinity-purified glycoprotein antigen enzymelinked immunotransfer blot (LLGP-EITB). Reactivity with any one of seven glycoprotein antigens (gp50, 42, 24, 18, 14, and 13) was considered a positive result. [18] [19] [20] The sensitivity of the LLGP-EITB is reported to be 98% and its specificity reaches 100% in patients with two or more viable brain lesions as demonstrated by neuroimaging.
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Data analysis
Differences between the individuals with epilepsy and controls were examined using t-tests for continuous variables and chi square tests for categorical variables.
Results
Demographics
We accrued 249 individuals with epilepsy and 245 agematched controls (Table 1) . Of those with epilepsy who participated in this study, 12 reported an age of seizure onset less than 5 years of age and thus are excluded from this report. Another 15 individuals did not report age of seizure onset, but were included in the sample. The mean age of control subjects was 17.5 years and that of the epilepsy group was 18.3 years (t = 1.56, p > 0.1). There were 53% male and 47% female in the epilepsy group and 57% male and 43% female in the control group (x 2 = 1.25, p > .0.1). Mean age of seizure onset was at 12.2 years. Sixty-eight percent (68%) of the epilepsy group had generalized convulsive seizures with 24% having localization-related epilepsy with secondary generalized seizures. Sixty percent (60%) of the individuals with epilepsy reported having relatives with epilepsy. The majority (67.7%) of the individuals with epilepsy began to have seizures at age 12 years or younger; 26.8% had onset in the teen years, 4.1% between the ages of 20 and 29, and 1.4% over the age of 40. Table 1 provides further details of the demographic and seizure-related variables. Analysis of data on potential risk factors for epilepsy revealed that prematurity, excessive alcohol consumption in the past, excessive drug use, as well as encephalitis, encephalopathy, and meningitis in childhood were not significant. Head injury with loss of consciousness was significant (p < .01) with a higher number of epilepsy cases (n = 18) than controls (n = 7). Measles in childhood approach significance (p < .057) with a somewhat higher rate amongst the epilepsy cases (n = 65) than those in the control group (n = 46).
Serology
Of the 494 samples tested, only 24 samples were positive on LLGP-EITB for cysticercosis. It should be noted that although they were not included in the analysis, none of the twelve individuals with seizure onset under 5 years of age were seropositive. Further, there was no significant difference in sero-positivity to T. solium between those with epilepsy (n = 11; 4.4%) and the controls (n = 13; 5.3%) ( Table 1) .
Discussion
Our data do not appear to support the hypothesis that individuals with epilepsy from Ngie have a higher percentage of seropositivity to T. solium than a matched control population. However this conclusion is limited somewhat by the fact that neurocysticercosis is a major cause of focal epilepsy and we included patients with both generalized and focal epilepsy in our study. This strategy was dictated by our inability to define focal epilepsy precisely using electroencephalography (EEG) given the absence of this resource in rural Cameroon. It is notoriously difficult to select out focal epilepsy based upon seizure semiology alone in patients who present with a history of generalized epilepsy because of the subtleties of secondarily generalized epilepsy. An example of the value of EEG in resolving this conundrum, as well as the over representation of focal epilepsy in patients in Cameroon with epilepsy may be found in the study by Prischich 5 where partial seizures defined by EEG were determined to represent 47% of patients based on seizure semiology before EEG and 64.7% following EEG.
With that caveat, these data appear to make it unlikely that neurocysticercosis plays a causative role in the high prevalence of epilepsy in this specific area of Cameroon and is in agreement with the report of Dongmo and collaborators. 1 As well, we examined a number of other potential risk factors, including prematurity, alcohol and drug abuse, encephalitis, encephalopathy, meningitis, head injury and measles. Only head injury reached significance, with a greater number of epilepsy cases reporting a history of head injury with loss of consciousness. However, these numbers are too small to account for the high rate of epilepsy. Further, our study design does not allow us to conclude what the causes of epilepsy in this area might be. Given our negative findings, the cause of the high rate of epilepsy in Ngie remains unknown. In the sample with epilepsy it In addition to the concern expressed above re focal epilepsy, there are additional limitations to this study. First, we did not do CT scans on the epilepsy and control cohorts, Since CT is the gold standard for making the diagnosis of neurocysticercosis, we cannot confirm whether any of the participants had this disorder. It simply was not possible to perform a CT scan on our subjects given the severe limitations of resources in the rural part of Cameroon in which this study was carried out. For the same reasons, even a simple skull film to look for intracranial calcifications was not feasible. Second, the detection of antibodies against T. solium by EITB in blood samples reflects a history of contact with the parasite rather than a real infestation by the metacestodes of T. solium. However, in some populations associations between seropositivity, neurocysticercosis and epilepsy have been demonstrated. 18 Finally, a major consideration for working in the field in rural Cameroon is that the Agn ELISA cannot be performed on fingerstick blood. It was never practical or feasible to do venipunctures on our cohorts.
Conclusion
These data do not support the hypothesis that those individuals in the Ngie sub-division of Momo who have epilepsy have a higher percentage of seropositivity to T. solium than a matched control population. The data make it highly unlikely that cysticercosis plays a causative role in the increased prevalence of epilepsy in this region of Cameroon. These results and previously published data suggest that the high prevalence of epilepsy reported in some areas in Cameroon could be attributed to a combination of many factors and not just one risk factor.
